2024 / 01

Next Paper
DOI: 10.24075/medet.2024.001

REVIEW

Bioethical approach to estimation of pharmacoepidemiological and pharmacoeconomic aspects of psoriasis treatment

Samarina EI, Lileeva EG, Rybachkova JV
About authors

Yaroslavl State Medical University, Yaroslavl, Russia

Correspondence should be addressed: Elena G. Lileeva
Revolutsionnaya Str., bld. 5, Yaroslavl, 150000, Russia; ur.xednay@6002aveelile

About paper

Author contribution: the authors reviewed literature data regarding the study of pharmacoepidemiological and pharmacoeconomic aspects of psoriasis treatment. The authors have made equal contributions into writing the article.

Received: 2024-01-24 Accepted: 2024-02-20 Published online: 2024-03-11
|
  1. Klinicheskiye rekomendatsii «Psoriaz». Available from URL: http://cr.rosminzdrav.ru/#!/recomend/866 (accessed 15.12.2023). Russian.
  2. Fedotova VP, Dyudyuna AD, Stepanenko VI. Dermatovenerologiya. Uchebnoye posobiye dlya vrachey i vrachey-internov. Izd. 2-ye. rus. Dnepropetrovsk — Kiyev. Izd-vo «Svidler AL». 2011; 652 s. Russian.
  3. Vsemirnyy doklad o probleme psoriaza. Available from URL: https://apps.who.int/iris/handle/10665/204417 (accessed 15.12.2023). Russian.
  4. Kubanov AA, Bogdanova Ye V. «Epidemiologiya psoriaza sredi naseleniya starshe trudosposobnogo vozrasta i ob”yemy okazyvayemoy spetsializirovannoy meditsinskoy pomoshchi bol’nym psoriazom v Rossiyskoy Federatsii v 2010–2019 g.». Vestnik dermatologii i venerologii. 2020; 96(5): 07–18. DOI: 10.25208/vdv1171-2020-96-5-07-18
  5. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. Journal of the American Academy of Dermatology. 2013; 69(5): 729–735.
  6. Armstrong AV, Rid S. Patofiziologiya, klinicheskaya kartina i lecheniye psoriaza: obzor. Dzhey Am Med Assots. 2020; 323(19): 1945–1960. Russian.
  7. Ramik L, Sator P. Mestnoye lecheniye vul’garnogo psoriaza. JDDG: Zhurnal Deutschen Dermatologischen Gesellschaft. 2023; 21: 631–642. DOI: 10.1111/ddg.15042
  8. Gerasimov VB, Khokhlov AL, Karpov OI. Farmakoekonomika i farmakoepidemiologiya — praktika priyemlemykh resheniy. 2005; 1: 14–15. Russian.
  9. Ohata C, Ohyama B, Katayama E, et al. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: a single-center experience. J Dermatol. 2020; 47(4):405–408. DOI: 10.1111/1346-8138.15247.
  10. Hayashida K, Murakami G, Matsuda S, et al. History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan. J Epidemiol. 2021;31(1):1–11. DOI: 10.2188/jea. JE20200288.
  11. Dovzhanskiy SI, Utts SR. Psoriaz ili psoriaticheskaya bolezn’ v 2-kh ch. Saratov. Izd-vo Saratovsk. un-ta. 1992;(1): 176 s.; 1992;(1): 96. Russian.
  12. Zil’berberg NV, Kashcheyeva YaV, Kiseleva NV, Kokhan MM. Opyt terapii bol’nykh psoriazom preparatom metotreksat v forme podkozhnykh i vnutrimyshechnykh in”yektsiy. Available from URL: https://www.lvrach.ru/2021/11/15438141(accessed 15.12.2023). Russian.
  13. Nast A, Al’tenburg A, Ogyusten M, et al. Nemetskoye rukovodstvo S3 po lecheniyu obyknovennogo psoriaza, adaptirovannoye iz EuroGuiDerm. Tseli lecheniya i rekomendatsii po lecheniyu. J Dtsch Dermatol Ges. 2021;19(6):934–1150. Russian.
  14. Langenbrukh A, Radtke MA, Yakobi A, et al. Kachestvo lecheniya psoriaza v Germanii: rezul’taty natsional’nogo issledovaniya zdravookhraneniya «PsoHealth3». Arka Dermatol Res. 2016;308(6):401–408. Russian.
  15. Gallyamova YuA, Asoskova AV. Metotreksat v dermatologii: ot teorii k praktike. Lechashchiy Vrach. 2021; 5 (24): 46–51. Russian.
  16. Nash P, Coates LC, Fleischmann R, et al. Efficacy of tofacitinib for the treatmentof psoriatic arthritis: Pooled analysis of two phase 3 studies. Rheumatol Ther. 2018;5(2):567–82.
  17. Instruktsiya po meditsinskomu primeneniyu preparata Skayrizi. Available from URL: http://grls.rosminzdrav.ru/Default dostup 01.07.2023. (accessed 15.12.2023). Russian.
  18. Instruktsiya po meditsinskomu primeneniyu preparata Gusel’kumab. Available from URL: http://grls.rosminzdrav.ru/ Default dostup 01.07.2023 (accessed 15.12.2023). Russian.
  19. Instruktsiya po meditsinskomu primeneniyu preparata Sekukinumab. Available from URL: http://grls.rosminzdrav.ru/ Default dostup 01.07.2023. (accessed 15.12.2023). Russian.
  20. Instruktsiya po meditsinskomu primeneniyu preparata Netakimab. Available from URL: http://grls.rosminzdrav.ru/Default dostup 01.07.2023. (accessed 15.12.2023). Russian.
  21. Instruktsiya po meditsinskomu primeneniyu preparata Iksekizumab. Available from URL: http://grls.rosminzdrav.ru/ Default dostup 01.07.2023. (accessed 15.12.2023). Russian.
  22. Instruktsiya po meditsinskomu primeneniyu preparata Adalimumab. Available from URL: http://grls.rosminzdrav.ru/ Default dostup 01.07.2023. (accessed 15.12.2023). Russian.
  23. Perrone V, Losi S, Filippi E, et al. Analysis of the pharmacoutilization of biological drugs in psoriatic arthritis patients: a real-world retrospective study among an Italian population. Rheumatol Ther. 2022;9(3):875–890. DOI: 10.1007/s40744-022-00440-1.
  24. Colombo D, Bianchi L, Fabbrocini G, et al. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: results of the CANOVA study. Dermatol Ther. 2022;35(1):15166.
  25. Xu C, Teeple A, Wu B, et al. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. J Dermatolog Treat. 2022; 33(4): 2270–2277. DOI: 10.1080/09546634.2021.1950600
  26. Tolkacheva DG, Sokolova VD, Mladov VV. Effektivnost’ i bezopasnost’ targetnykh lekarstvennykh preparatov v terapii vzroslykh patsiyentov so srednetyazhelym i tyazhelym vul’garnym psoriazom v RF. Meditsinskiye tekhnologii. Otsenka i vybor. 2019; 4:76–86. Russian.
  27. Rudakova AV, Tolkacheva DG, Sokolova VD. Farmakoekonomicheskiye aspekty terapii psoriaticheskogo artrita srednetyazheloy i tyazheloy stepeni. 2021;14 (2):7–8. Russian.
  28. Sinichkin AA. Tochki opory v prinyatii resheniya o naznachenii genno-inzhenernykh biologicheskikh preparatov patsiyentam s psoriaticheskim artritom. Effektivnaya farmakoterapiya. 2019; 15(6): 46–50. Russian.
  29. Yurchenko AV, Taube AA, Shubnikova YeV, et al. Izucheniye potentsiala rossiyskogo rynka lekarstvennykh preparatov na osnove monoklonal’nykh antitel. Farmakoekonomika: teoriya i praktika. 2022;10(3): 5–11. DOI: 10.30809/phe.3.2022.1. Russian.
  30. Sokolova VD, Sableva NA, Mladov VV, Tolkacheva DG. Effektivnost’ targetnykh lekarstvennykh preparatov v terapii vzroslykh patsiyentov so srednetyazhelym i tyazhelym vul’garnym psoriazom v Rossiyskoy Federatsii: obnovleniye sistematicheskogo obzora. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2022; 15(1): 131–144. DOI: 10.17749/2070-4909/farmakoekonomika.2022.128. Russian.